Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion

Dept. of Pediatrics, Cincinnati Children's Hospital Medical Center, Univ. of Cincinnati, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
AJP Heart and Circulatory Physiology (Impact Factor: 4.01). 01/2006; 289(6):H2747-51. DOI: 10.1152/ajpheart.01280.2004
Source: PubMed

ABSTRACT The MAPK family member p38 is activated in the heart after ischemia-reperfusion (I/R) injury. However, the cardioprotective vs. proapoptotic effects associated with p38 activation in the heart after I/R injury remain unresolved. Another issue to consider is that the majority of past studies have employed the rodent as a model for assessing p38's role in cardiac injury vs. protection, while the potential regulatory role in a large animal model is even more uncertain. Here we performed a parallel study in the mouse and pig to directly compare the extent of cardiac injury after I/R at baseline or with the selective p38 inhibitor SB-239063. Infusion of SB-239063 5 min before ischemia in the mouse prevented ischemia-induced p38 activation, resulting in a 25% reduction of infarct size compared with vehicle-treated animals (27.9 +/- 2.9% vs. 37.5 +/- 2.7%). In the pig, SB-239063 similarly inhibited myocardial p38 activation, but there was no corresponding effect on the degree of infarction injury (43.6 +/- 4.0% vs. 41.4 +/- 4.3%). These data suggest a difference in myocardial responsiveness to I/R between the small animal mouse model and the large animal pig model, such that p38 activation in the mouse contributes to acute cellular injury and death, while the same activation in pig has no causative effect on these parameters.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) remains a major cause of death and hospitalization worldwide. Despite medical advances, the prognosis of HF remains poor and new therapeutic approaches are urgently needed. The development of new therapies for HF is hindered by inappropriate or incomplete preclinical studies. In these guidelines, we present a number of recommendations to enhance similarity between HF animal models and the human condition in order to reduce the chances of failure in subsequent clinical trials. We propose different approaches to address safety as well as efficacy of new therapeutic products. We also propose that good practice rules are followed from the outset so that the chances of eventual approval by regulatory agencies increase. We hope that these guidelines will help improve the translation of results from animal models to humans and thereby contribute to more successful clinical trials and development of new therapies for HF.
    Journal of Cardiovascular Translational Research 01/2015; DOI:10.1007/s12265-015-9606-8 · 2.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 3',4'-dihydroxyflavonol (DiOHF) is cardioprotective against ischemia/reperfusion (I/R) injury. The biological activities of flavonols are associated with kinase modulation to alter cell signalling. We thus investigated the effects of DiOHF on the activation of mitogen-activated protein kinases that regulate the cardiac stress response. In an ovine model of I/R, JNK, p38MAPK, ERK and AKT were activated, and NP202, a pro-drug of DiOHF, reduced infarct size and inhibited JNK and p38MAPK activation while ERK and AKT phosphorylation were unaltered. Similarly, in cultured myoblasts, DiOHF pretreatment preserved viability and inhibited activation of JNK and p38MAPK but not ERK in response to acute oxidative and chemotoxic stress. Furthermore, DiOHF prevented stress-activation of the direct upstream regulators MAPK kinases (MKKs) 4/7 and MKK3/6 respectively. We utilized small-molecule affinity purification and identified Ca2+/calmodulin-dependent protein kinase II (CaMKII) as a kinase targeted by DiOHF and demonstrated potent CaMKII inhibition by DiOHF in vitro. Moreover, the specific inhibition of CaMKII with KN-93, but not KN-92, completely attenuated oxidative stress-induced activation of JNK and p38MAPK. Our studies indicate DiOHF inhibition of CaMKII and attenuation of MKK3/6 → p38MAPK and MKK4/7 → JNK signalling as a requirement for the protective effects of DiOHF against stress stimuli and myocardial I/R injury.
    Biochemical Journal 09/2013; DOI:10.1042/BJ20121538 · 4.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor-α (TNF-α) is a potent proinflammatory cytokine involved in a variety of disease pathologies, including ischemia/reperfusion (I/R) injuries in transplantation. The interaction of TNF-α with its cognate receptor TNF receptor I (TNFRI) results in the activation of signal transduction pathways that regulate either cell survival or cell death. Hepatocytes express TNFRI and respond to TNF-α released by resident Kupffer cells as well as leukocytes that migrate to the liver during I/R injury. Upon binding TNF-α, the hepatocyte proliferates or undergoes apoptosis or necroptosis. The decision by the cell to commit to one path or the other is not understood. The damaged tissue exhibits cell death and hemorrhaging from the influx of immune mediators. TNF-α inhibitors ameliorate the injury in animal models, suggesting that lowering (but not eliminating) TNF-α levels shifts the balance of TNF-α toward its beneficial functions. We review TNF-α signal transduction pathways and the role of TNF-α in liver I/R injury. Because TNF-α plays an important role in hepatocyte proliferation, complete inhibition of TNF-α is not desirable in treating liver I/R injury. The strategy for developing pharmacological therapies may be the identification of specific intermediates in the TNF-α/TNFR1 signal transduction pathway and directed targeting of proapoptotic and pronecroptotic events.
    Ochsner Journal 01/2013; 13(1):119-30.